Miami, FL (PRWEB) February 11, 2014
Global Stem Cells Group, Bioheart, Inc., and Paul Perito Urology announce plans to launch stem cell clinical trials for treatment of Erectile Dysfunction (ED).
Paul Perito, M.D. of Perito Urology in Coral Gables, Florida and the principal investigator of the trial study, titled, "An Open-label, Non-randomized, Single-center Study to Assess the Safety and Effects of Autologous Adipose-derived Stromal Cells Delivered into the Corpus Cavernosum in Patients with Erectile Dysfunction," aims to assess the safety and efficacy of stem cell implantation therapy in patients with ED.
The cell therapy in this study will be composed of stem cells derived from a patients own adipose (fat) tissue, harvested by syringe liposuction. The adipose stem cells will then be delivered into the corpus cavernosum of the penis.
Clinical trials will be held at Perito Urology, in cooperation with Global Stem Cells Group and Bioheart. Up to 20 patients will be enrolled.
Fort Myers Florida-based Emcyte Corporation, a leading provider of biotechnology products for platelet rich plasma and bone marrow concentrate grafting procedures, will be providing systems and kits to be used in the trial.
To learn more about Global Stem Cells Group's clinical trials, and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
See more here:
Global Stem Cells, Inc., Bioheart, Inc., and Paul Perito Urology Announce Plans to Launch Stem Cell Clinical Trials ...